PMID- 32517691
OWN - NLM
STAT- MEDLINE
DCOM- 20210113
LR  - 20210113
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 16
IP  - 1
DP  - 2020 Jun 9
TI  - Duration of immunity against heterologous porcine parvovirus 1 challenge in gilts 
      immunized with a novel subunit vaccine based on the viral protein 2.
PG  - 184
LID - 10.1186/s12917-020-02394-4 [doi]
LID - 184
AB  - BACKGROUND: Porcine parvovirus 1 (PPV1) is widespread in commercial pig farms 
      worldwide and has a significant impact to the swine industry. Long-lasting 
      immunity achieved by means of vaccination is the main tool to prevent PPV1 
      infection and its associated clinical signs. Here we evaluated the duration of 
      immunity (DOI) conferred by a novel subunit vaccine based on the viral protein 
      (VP) 2 of PPV1, named ReproCyc(R) ParvoFLEX. The DOI was assessed at 6 months 
      post-vaccination following the standard vaccination scheme (phase I) or after 
      re-vaccination (phase II) with a single injection administered 24 weeks after the 
      basic vaccination scheme. A total of 46, five to six-month-old gilts, free of 
      PPV1 and porcine reproductive and respiratory syndrome virus (PRRSV), were 
      randomly assigned to 6 groups (three in each phase): the negative control groups 
      were inoculated with sodium chloride (NaCl), the vaccinated groups were immunized 
      with the PPV1 subunit vaccine and the strict controls were neither treated nor 
      challenged. Subsequently, the negative control and vaccinated groups from each 
      phase were challenged with a heterologous PPV1 strain. Infection of fetuses was 
      the primary outcome parameter for efficacy, though other supportive parameters 
      were PPV1 viremia and serological status of the gilts and the condition of their 
      fetuses (i.e. normal, autolytic, or mummified). RESULTS: All gilts vaccinated 
      against PPV1 tested seropositive at challenge and viremia after challenge was 
      detectable only in the non-vaccinated animals. In this regard, fetuses positive 
      to PPV1 by PCR were only found in litters from non-vaccinated sows. CONCLUSIONS: 
      These results point out that the immunity developed by the PPV1 subunit vaccine 
      is effective in terms of preventing viremia, transplacental infection of fetuses 
      and fetal death caused by PPV1 infection. ReproCyc(R) ParvoFLEX was demonstrated to 
      protect fetuses against heterologous PPV1 challenge with a DOI of 6 months after 
      vaccination.
FAU - Garcia-Morante, Beatriz
AU  - Garcia-Morante B
AUID- ORCID: 0000-0002-5610-9932
AD  - Centcinc, C/Montserrat de Casanovas 105, 08032, Barcelona, Spain. 
      bea.garciamorante@gmail.com.
FAU - Noguera, Marta
AU  - Noguera M
AD  - Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Strabetae 
      31, 30559, Hannover, Germany.
FAU - Klocke, Sonja
AU  - Klocke S
AD  - Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Strabetae 
      31, 30559, Hannover, Germany.
FAU - Sommer, Kathrin
AU  - Sommer K
AD  - Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG, Bemeroder Strabetae 
      31, 30559, Hannover, Germany.
FAU - Bridger, Philip
AU  - Bridger P
AD  - Boehringer Ingelheim Vetmedica GmbH, Binger Strabetae 173, 55216, Ingelheim, 
      Germany.
LA  - eng
GR  - Not applicable/Boehringer Ingelheim Animal Health, Inc./
PT  - Journal Article
DEP - 20200609
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Vaccines, Subunit)
RN  - 0 (Viral Proteins)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Female
MH  - Fetus/virology
MH  - Immunization/veterinary
MH  - Parvoviridae Infections/immunology/prevention & control/*veterinary
MH  - Parvovirus, Porcine/*immunology
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/veterinary/virology
MH  - Sus scrofa
MH  - Swine
MH  - Swine Diseases/prevention & control/*virology
MH  - Vaccination/veterinary
MH  - Vaccines, Subunit/administration & dosage/*immunology
MH  - Viral Proteins/immunology
MH  - Viral Vaccines/administration & dosage/immunology
PMC - PMC7285602
OTO - NOTNLM
OT  - Duration of immunity
OT  - Mass vaccination
OT  - Pigs
OT  - Porcine parvovirus
OT  - Subunit vaccine
OT  - Vaccine efficacy
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests: Boehringer Ingelheim 
      Animal Health, Inc. sponsored the clinical trials reported in this publication 
      through professional veterinary and research support. Dr. Beatriz Garcia Morante 
      is an external researcher consultant.
EDAT- 2020/06/11 06:00
MHDA- 2021/01/14 06:00
PMCR- 2020/06/09
CRDT- 2020/06/11 06:00
PHST- 2019/06/03 00:00 [received]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2021/01/14 06:00 [medline]
PHST- 2020/06/09 00:00 [pmc-release]
AID - 10.1186/s12917-020-02394-4 [pii]
AID - 2394 [pii]
AID - 10.1186/s12917-020-02394-4 [doi]
PST - epublish
SO  - BMC Vet Res. 2020 Jun 9;16(1):184. doi: 10.1186/s12917-020-02394-4.